Zeltia to press ahead with rejected cancer drug
February 4, 2004Zeltia has unveiled a three-year business plan to put itself back on track after lead cancer drug Yondelis was rejected …
Industry chair for communications body
February 3, 2004Stuart Rose has been named as the new chair of the Healthcare Communications Association (HCA), the first ever from the …
AstraZeneca emerges unscathed from $2.6 billion patent loss
February 3, 2004Strong growth in a new generation of products has helped AstraZeneca earn a memorable victory in overcoming $2.6 billion worth …
Managing medical education
February 3, 2004Over the years, Medical Education (med ed) and PR agencies have been an invaluable part of the marketing mix. Med …
Sanofi makes takeover bid for ‘weakened’ Aventis
January 26, 2004Sanofi-Synthelabo has made a pre-emptive E47 billion takeover bid for Aventis with the aim of creating the world's third-biggest drugmaker …
Pfizer takes giant step forward
January 23, 2004The pharmaceutical industry's biggest company Pfizer has restated its dominance with renewed growth in sales and earnings for the fourth …
Abbott raises sales expectations for Humira
January 21, 2004Abbott Laboratories has raised its sales forecast for Humira, its new rheumatoid arthritis treatment, to $700 million in 2004 after …
Pfizer to sell diagnostics business
January 21, 2004Pfizer has agreed to sell its Swedish in-vitro allergy and autoimmune diagnostic business to private equity groups Triton and PPM …
Aventis and Sanofi attempt to quash merger rumours
January 19, 2004Sanofi-Synthelabo and Aventis have been forced to officially deny they are in merger talks after speculation sent shares soaring in …
Streamlined research
January 19, 2004For many years the pharmaceutical industry has been promising that they were on the verge of a boom in the …
Sizing up med ed
January 19, 2004The use of medical education in the pharmaceutical industry has never been greater. Starting from the early stages of clinical …
Too close for comfort?
January 19, 2004Medical Communications, Sales and Marketing doctors, industry reputation
The pharmaceutical industry's increasing scale and influence means that no part of its conduct is above scrutiny, and criticism of …
Pfizer to sell-off sixty OTC products in Europe
January 16, 2004Pfizer is looking to sell off about 60 non-core consumer products in Europe to position the business for long-term growth …
Eloxatin approved in US as first line treatment
January 16, 2004Sanofi-Synthelabo's Eloxatin has received US approval for use as first line treatment of colorectal cancer in combination with standard treatment …
W.A.R marshals forces for healthcare push
January 16, 2004Independent marketing communications agency Ware Anthony Rust has consolidated its healthcare accounts into a new division prompted by the sector's …
Genzyme to set up research facility in UK
January 16, 2004Genzyme, one of the US' most successful biotechnology companies has chosen Cambridge as the location of its first research centre …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
